Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) gapped up prior to trading on Friday . The stock had previously closed at $25.61, but opened at $26.42. Dyne Therapeutics shares last traded at $25.71, with a volume of 40,896 shares trading hands.
Analyst Upgrades and Downgrades
A number of analysts have weighed in on the company. HC Wainwright reaffirmed a "buy" rating and issued a $55.00 price target on shares of Dyne Therapeutics in a research report on Wednesday, November 13th. Raymond James upgraded Dyne Therapeutics to a "strong-buy" rating in a report on Thursday. Chardan Capital reiterated a "buy" rating and set a $50.00 price target on shares of Dyne Therapeutics in a report on Wednesday, November 13th. Oppenheimer reissued an "outperform" rating and issued a $55.00 price target on shares of Dyne Therapeutics in a research report on Tuesday, September 3rd. Finally, JPMorgan Chase & Co. downgraded shares of Dyne Therapeutics from an "overweight" rating to a "neutral" rating and decreased their price objective for the stock from $43.00 to $35.00 in a report on Thursday, October 24th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $50.42.
View Our Latest Stock Report on Dyne Therapeutics
Dyne Therapeutics Stock Up 0.5 %
The company has a market capitalization of $2.62 billion, a price-to-earnings ratio of -7.23 and a beta of 1.09. The business has a fifty day simple moving average of $30.39 and a two-hundred day simple moving average of $35.20.
Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.71) by ($0.25). As a group, equities analysts predict that Dyne Therapeutics, Inc. will post -3.45 earnings per share for the current fiscal year.
Insiders Place Their Bets
In related news, SVP Richard William Scalzo sold 1,390 shares of the firm's stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $34.55, for a total value of $48,024.50. Following the completion of the sale, the senior vice president now owns 98,568 shares of the company's stock, valued at $3,405,524.40. This trade represents a 1.39 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Dirk Kersten sold 79,411 shares of the stock in a transaction on Friday, September 20th. The shares were sold at an average price of $36.45, for a total value of $2,894,530.95. Following the completion of the transaction, the director now owns 234,127 shares in the company, valued at $8,533,929.15. The trade was a 25.33 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 180,046 shares of company stock valued at $6,300,265. 20.77% of the stock is currently owned by corporate insiders.
Institutional Trading of Dyne Therapeutics
Institutional investors have recently bought and sold shares of the business. FMR LLC increased its stake in shares of Dyne Therapeutics by 69.7% in the 3rd quarter. FMR LLC now owns 9,026,697 shares of the company's stock valued at $324,239,000 after acquiring an additional 3,707,734 shares during the last quarter. RTW Investments LP grew its holdings in Dyne Therapeutics by 6.8% during the third quarter. RTW Investments LP now owns 6,818,641 shares of the company's stock valued at $244,926,000 after purchasing an additional 431,503 shares during the period. Janus Henderson Group PLC raised its holdings in Dyne Therapeutics by 47.3% in the third quarter. Janus Henderson Group PLC now owns 6,813,163 shares of the company's stock worth $244,755,000 after purchasing an additional 2,189,339 shares during the period. RA Capital Management L.P. raised its holdings in Dyne Therapeutics by 5.5% in the third quarter. RA Capital Management L.P. now owns 6,381,144 shares of the company's stock worth $229,211,000 after purchasing an additional 331,940 shares during the period. Finally, State Street Corp boosted its position in shares of Dyne Therapeutics by 13.8% during the third quarter. State Street Corp now owns 3,641,859 shares of the company's stock worth $130,816,000 after purchasing an additional 440,890 shares in the last quarter. Institutional investors and hedge funds own 96.68% of the company's stock.
About Dyne Therapeutics
(
Get Free Report)
Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
Featured Stories
Before you consider Dyne Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dyne Therapeutics wasn't on the list.
While Dyne Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.